Woippy, France – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, is pleased to announce the signing of an exclusive distribution agreement with VELA Operations Singapore for Europe, the Middle East and Africa (EMEA). The agreement will become fully effective in January 2026, with a non-exclusive transition phase starting July 2025.
Technological synergy
This partnership also opens the door to strong technological synergies. ABL's kits and software solutions are being adapted for use on VELA's automated platforms, enabling laboratories to combine ABL’s scientific depth and flexibility with the automation power of VELA systems. This integration will help enhance customer satisfaction, simplify workflows, and accelerate time to results.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer